Olinvacimab
- Generic Name
- Olinvacimab
- Drug Type
- Biotech
- CAS Number
- 2095504-49-5
- Unique Ingredient Identifier
- VFH55IZ5VI
- Background
Olinvacimab is under investigation in clinical trial NCT03033524 (Trial to Evaluate the Safety of Ttac-0001(tanibirumab) in Recurrent Glioblastoma).
Olinvacimab With Pembrolizumab in Patients With mTNBC
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- PharmAbcine
- Target Recruit Count
- 30
- Registration Number
- NCT04986852
- Locations
- 🇦🇺
Hollywood Private Hospital, Nedlands, Western Australia, Australia
A Phase lb/ll, Open Label, Single Arm Study With Olinvacimab and Capecitabine in mCRC Patients (OLCAP)
Phase 1
Withdrawn
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Korean Cancer Study Group
- Registration Number
- NCT04751955
TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab
- First Posted Date
- 2019-02-27
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- PharmAbcine
- Target Recruit Count
- 19
- Registration Number
- NCT03856099
- Locations
- 🇦🇺
Austin Hospital, Heidelberg, Victoria, Australia
🇺🇸Stanford Avanced Medical Center, Stanford, California, United States
🇺🇸Florida Hospital Cancer Institute & Florida Hospital Orlando, Orlando, Florida, United States
Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- PharmAbcine
- Target Recruit Count
- 12
- Registration Number
- NCT03033524
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath